Clinical Trial Detail

NCT ID NCT03473925
Title Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate cancer

non-small cell lung carcinoma

colorectal cancer

Therapies

Navarixin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.